Evolus has reported positive data from a Phase III clinical trial evaluating prabotulinumtoxinA in comparison with onabotulinumtoxinA for the treatment of patients with glabellar lines, also known as ‘frown lines’ between the eyebrows.

EVB-003 is a 150-day, multicentre, randomised, double-blind, active and placebo-controlled, single-dose non-inferiority study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Approximately 540 adults aged 18 or older were enrolled with moderate to severe glabellar lines at maximum frown, as assessed by the investigator on the four-point glabellar line scale.

Enrolled subjects stated that they felt their glabellar lines had an important psychological impact.

As part of the trial, patients were randomised at 5:5:1 ratio to receive a single treatment of 20 U prabotulinumtoxinA, 20 U onabotulinumtoxinA or placebo.

The primary efficacy objective of the EVB-003 trial was measured on day 30 and a responder was defined as a GLS score of zero or one at maximum frown following evaluation by the trial investigator.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The trial met its primary endpoint of non-inferiority at day 30, with responder rates of 87.2% in the prabotulinumtoxinA group, 82.8% in the onabotulinumtoxinA group, and 4.2% for placebo.”

From the total enrolled patients, 245 received prabotulinumtoxinA, 246 had onabotulinumtoxinA, while 49 were given placebo.

According to Evolus, the trial met its primary endpoint of non-inferiority at day 30, with responder rates of 87.2% in the prabotulinumtoxinA group, 82.8% in the onabotulinumtoxinA group, and 4.2% for placebo.

The trial reported 15.5% drug-related adverse events in prabotulinumtoxinA group, as well as 14.6% and 4.1% similar events in the onabotulinumtoxinA and placebo groups respectively. No serious adverse events were reported that were examined as study-drug related.

PrabotulinumtoxinA is a 900 kilodalton (kDa) purified botulinum toxin type A complex and its biologics licence application (BLA) is currently under review of the US Food and Drug Administration (FDA).

OnabotulinumtoxinA is also a 900 kDa botulinum toxin type A complex.